Please login to the form below

Not currently logged in
Email:
Password:

myelofibrosis

This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis. ... Momelotinib offers a differentiated treatment option that could address the significant unmet medical needs of myelofibrosis patients with

Latest news

More from news
Approximately 10 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis

  • Deal Watch January 2018

    Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other indications could amount to $1.4bn. ... Acquisition company - remaining 90%. 9, 000. Impact

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The other side of … blood cancer

    He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called  myelofibrosis.

  • THE OTHER SIDE OF...BLOOD CANCER

    Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called  myelofibrosis.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...